Your browser doesn't support javascript.
loading
Insulin and Body Mass Index Decrease Serum Soluble Leptin Receptor Levels in Humans.
Sommer, Christine; Vangberg, Kjersti G; Moen, Gunn-Helen; Evans, David M; Lee-Ødegård, Sindre; Blom-Høgestøl, Ingvild K; Sletner, Line; Jenum, Anne K; Drevon, Christian A; Gulseth, Hanne L; Birkeland, Kåre I.
Afiliación
  • Sommer C; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, 0424 Oslo, Norway.
  • Vangberg KG; Department of Endocrinology, Morbid Obesity and Preventive Medicine, Oslo University Hospital, 0424 Oslo, Norway.
  • Moen GH; Department of Nutrition, Institute of Basic Medical Sciences, Faculty Medicine, University of Oslo, 0317 Oslo, Norway.
  • Evans DM; Institute of Clinical Medicine, University of Oslo, 0318 Oslo, Norway.
  • Lee-Ødegård S; Institute for Molecular Bioscience, The University of Queensland, St Lucia QLD 4072, Australia.
  • Blom-Høgestøl IK; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba QLD 4102, Australia.
  • Sletner L; Population Health Science, Bristol Medical School, University of Bristol, BS8 1QU Bristol, UK.
  • Jenum AK; Department of Public Health and Nursing, K.G. Jebsen Center for Genetic Epidemiology, NTNU, Norwegian University of Science and Technology, 7491 Trondheim, Norway.
  • Drevon CA; Institute for Molecular Bioscience, The University of Queensland, St Lucia QLD 4072, Australia.
  • Gulseth HL; The University of Queensland Diamantina Institute, The University of Queensland, Woolloongabba QLD 4102, Australia.
  • Birkeland KI; MRC Integrative Epidemiology Unit, University of Bristol, BS8 2BN Bristol, UK.
J Clin Endocrinol Metab ; 108(5): 1110-1119, 2023 04 13.
Article en En | MEDLINE | ID: mdl-36459457
CONTEXT: Serum soluble leptin receptor (sOb-R) may protect against future type 2 diabetes or serve as a marker for protective features, but how sOb-R is regulated is largely unknown. OBJECTIVE: This work aimed to test how serum sOb-R is influenced by glucose, insulin, body fat, body mass index (BMI), food intake, and physical activity. METHODS: We performed an epidemiological triangulation combining cross-sectional, interventional, and Mendelian randomization study designs. In 5 independent clinical studies (n = 24-823), sOb-R was quantified in serum or plasma by commercial enzyme-linked immunosorbent assay kits using monoclonal antibodies. We performed mixed-model regression and 2-sample Mendelian randomization. RESULTS: In pooled, cross-sectional data, leveling by study, sOb-R was associated inversely with BMI (ß [95% CI] -0.19 [-0.21 to -0.17]), body fat (-0.12 [-0.14 to -0.10), and fasting C-peptide (-2.04 [-2.46 to -1.62]). sOb-R decreased in response to acute hyperinsulinemia during euglycemic glucose clamp in 2 independent clinical studies (-0.5 [-0.7 to -0.4] and -0.5 [-0.6 to -0.3]), and immediately increased in response to intensive exercise (0.18 [0.04 to 0.31]) and food intake (0.20 [0.06 to 0.34]). In 2-sample Mendelian randomization, higher fasting insulin and higher BMI were causally linked to lower sOb-R levels (inverse variance weighted, -1.72 [-2.86 to -0.58], and -0.20 [-0.36 to -0.04], respectively). The relationship between hyperglycemia and sOb-R was inconsistent in cross-sectional studies and nonsignificant in intervention studies, and 2-sample Mendelian randomization suggested no causal effect of fasting glucose on sOb-R. CONCLUSION: BMI and insulin both causally decreased serum sOb-R levels. Conversely, intensive exercise and food intake acutely increased sOb-R. Our results suggest that sOb-R is involved in short-term regulation of leptin signaling, either directly or indirectly, and that hyperinsulinemia may reduce leptin signaling.
Asunto(s)
Palabras clave

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Resistencia a la Insulina / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Endocrinol Metab Año: 2023 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Resistencia a la Insulina / Diabetes Mellitus Tipo 2 Tipo de estudio: Clinical_trials / Observational_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Clin Endocrinol Metab Año: 2023 Tipo del documento: Article País de afiliación: Noruega Pais de publicación: Estados Unidos